EGFR and non-small cell lung carcinoma: In NSCLC, epigenetic alterations increase the activation of OXPHOS, leading to acquired EGFR‐TKI resistance, and IACS‐010759 successfully reversed gefitinib resistance in a patient‐derived xenograft model in vivo [238].